Cognition - OtherNCT06690619
Effects of Alpha-GPC on Muscle Power, GH Levels, and Cognitive Function
A study testing 315 mg Alpha-GPC and 630 mg Alpha-GPC in people with Cognition - Other and Strength Outcomes, run by Lindenwood University at 1 site in United States.
Trial summary
Purpose: To determine the effects of low dose and high dose Alpha-GPC on cognitive performance, muscle performance, and serum growth hormone levels. Design: Randomized, three-arm, within-subject crossover Study Participants: 21 apparently healthy men to be recruited at a single investigational center in Northeast Ohio… Read more about this study
- Who is it for?
- Ages 25 to 55 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Cognition - Other, Strength Outcomes
- What is being tested?
- 315 mg Alpha-GPC and 630 mg Alpha-GPC
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 20 participants
- Where
- 1 siteUnited States
- Study dates
- 9 Jan 2024to 11 Jun 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 55 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Voluntarily provide signed and dated informed consent.
- Be in good health as determined by medical history and routine blood chemistries.
- Age between 25 and 55 years (inclusive).
- Body Mass Index of 18.5-34.9 (inclusive).
- Body weight of at least 120 pounds.
- Resistance training history of at least 2 years.
Show all 9Show fewer
- Normotensive (supine, resting systolic blood pressure <140 mm Hg and diastolic blood pressure < 90 mm Hg.
- Normal supine, resting heart rate (< 90 per minute).
- Willing to duplicate their previous 24-hour diet, refrain from alcohol and caffeine for 24 hr prior to each trial, refrain from exercise 48 hr prior to each trial, refrain from any nutrients that might affect choline 24 hr prior to each trial, and fast for 8 hours prior to each trial.
Who cannot join
- Highly trained or competitive athletes.
- History of diabetes, asthma, gout, fibromyalgia or clinical diagnosis of IBS/IBD.
- History of malignancy in the previous 5 years except for non-melanoma skin cancer (basal cell cancer or squamous cell cancer of the skin).
- History of psychiatric disorder.
- History of hepatorenal, musculoskeletal, autoimmune, or neurologic disease.
- Use of any dietary supplements that may confound the study or its endpoints, including creatine, BCAA, HMB, betaine, beta-alanine, etc.
Show all 18Show fewer
- Use of stimulants or anxiety or ADHD medication.
- Caffeine intake of three or more cups of coffee or equivalent (>400 mg) per day.
- Alcohol consumption (more than 2 standard alcoholic drinks per day or more than 10 drinks per week) or drug abuse or dependence.
- Smokers.
- Clinically significant abnormal laboratory results at screening.
- Prior gastrointestinal bypass surgery (Lapband, etc.).
- Other known gastrointestinal or metabolic diseases that might impact nutrient absorption or metabolism, e.g., short bowel syndrome, diarrheal illnesses, history of colon resection, gastro paresis, Inborn-Errors-of-Metabolism (such as PKU).
- Chronic inflammatory condition or disease (e.g., rheumatoid arthritis, Crohn's disease, ulcerative colitis, Lupus, HIV/AIDS, etc.).
- Concomitant use of corticosteroids or testosterone replacement therapy (ingestion, injection, or transdermal).
- Known allergy or sensitivity to any ingredient in the test formulations as listed in the Certificates-of-Analysis.
- Currently participating in another research study with an investigational product or have been in another research study in the past 30 days.
- Any other diseases or conditions that, in the opinion of the medical staff, could confound the primary endpoint or place the subject at increased risk of harm if they were to participate.
Trial locations and contacts
1 site in 1 country.
United States1 site
Center for Applied Health Sciences
Canfield, Ohio, 44406
About this study
Purpose: To determine the effects of low dose and high dose Alpha-GPC on cognitive performance, muscle performance, and serum growth hormone levels.
Design: Randomized, three-arm, within-subject crossover
Read more
Study Participants: 21 apparently healthy men to be recruited at a single investigational center in Northeast Ohio
4 Study Visits
Study Visit 1: Participants will be screened for participation (i.e., medical history, routine blood work, background baseline diet)
Study Visit 2: Participants will ingest one of three supplements (a low dose α-GPC, a high dose α-GPC, or a placebo). Subjects will complete visual analog scale (VAS) questionnaires (assessing mood, motivation, alertness, and concentration) and a cognitive battery (Stroop, Flanker, and N-Back tests) 60 min post ingestion and approximately 3 hours post-ingestion, undergo upper body and lower body power testing and a lower body bout of moderate-intensity exercise 90 min post-ingestion. Also, subjects will undergo blood draws for levels of growth hormone at baseline (prior to supplementation) and 5, 15, 30, and 60 min post lower body bout of exercise. Vital signs and comprehensive side effect profile/ adverse event monitoring will take place throughout the duration of the study. The study will be conducted following ICH-GCP guidelines to ensure subject safety and scientific integrity of the data.
Study Visit 3 and 4 Identical to visit 2 with exception of different supplementation being provided. Supplement administration was randomized using a Latin square approach to reduce variability and enhance statistical power
Primary Outcomes: Upper and lower body peak force production, peak power production, and peak velocity
Secondary Outcomes: Cognitive performance on the Stroop test, Flanker, and N-Back test, serum growth hormone levels, mood, motivation, alertness, and concentration (as assessed by visual analog scales).
Tertiary/Safety Outcomes: Vital signs, side effect profile/AE monitoring
Read the detailed description
DIET:
- All subjects will be asked to maintain their usual dietary habits throughout the study.
- At screening, all subjects will complete a 24-hour diet recall from the day prior while refraining from any nutrients that might affect choline.
- To replicate screening conditions as closely as possible, subjects will follow their previously recorded 24-hour diet record and fast for 8 hours prior to each laboratory visit.
- An online application (Nutritionix) will be used to analyze their dietary consumption.
BLOODWORK:
•Blood draws will take place during each laboratory visit, and they will be performed by a study nurse or phlebotomist. At screening a single blood draw will be performed with a total blood volume of approximately 12 mL. During visits 2-4 serial blood draws will be performed before and 5-, 15-, 30-, and 60-min post ingestion of the investigational product. During visits 2-4, an intra-venous catheter (flexible tubing to enable blood sampling) will be inserted into an upper extremity vein. Blood samples will be collected up to 5 times over 4 hours.
EXERCISE TRAINING AND PHYSICAL ACTIVITY CONTROL
•Subjects will be asked to maintain their activities of daily living and abstain from exercise for 48 hours prior to each trial.
TEST PRODUCTS
- After qualifying for the study, subjects will be randomly assigned to receive a placebo, a low dose of α-GPC, and a high dose of α-GPC using a Latin Square design.
- Low dose of α-GPC (350 mg)
- High dose of α-GPC (700 mg)
- Placebo (containing maltodextrin)
- Supplements will be provided in identical-looking capsules with label directions and Study Protocol Number.
- Subjects will consume each supplement in the presence of the medical staff.
- There will be no less than one week between each trial, though this may be longer depending on scheduling.
- As stated earlier, subjects who withdraw from the study prior to completing all three trials may be replaced.
DETAILED STUDY PROCEDURES
Visit 1 (Screening)
- Medical history, safety blood work (CBC, CMP, and Lipid Panel)
- Body composition (bioimpedance-BIA)
- Baseline diet (24hr recall).
- Body weight
- Familiarization trial for the cognitive battery (Stroop, Flanker, and N-Back test).
Visits 2-4
- Subjective feelings of mood, motivation, alertness, and concentration will be assessed 60 minutes post ingestion and approximately 3 hours post-ingestion. All assessments will be made using 100 mm anchored visual analogue scales (VAS).
- Three repetitions of the Stroop (2-min tests), Flanker, and N-Back (90s tests) tests will be assessed 60 minutes post ingestion and approximately 3 hours post-ingestion.
- Stroop - https://www.psytoolkit.org/lessons/stroop.html
- Flanker - https://www.psytoolkit.org/experiment-library/flanker.html
- N-Back - https://www.lumosity.com/app/v4/games/speed-match-overdrive-web
- Upper and lower body muscular power will be assessed with a Tendo unit. For the upper body, the bench press throw using a submaximal load (i.e., 50% of 1RM) will be performed on a Smith machine. For the lower body, a vertical jump will be performed. Both tests will be performed 90 minutes post-ingestion.
- Moderate intensity lower body exercise bout consisting of 6 sets of 10 repetitions at 70% of 1RM of squats using a metronome for cadence (15 reps per min) on a Smith machine approximately 2 hours post-ingestion.
- Growth hormone will be measured via blood draw before supplementation ingestion and 5, 15, 30, and 60 min post lower body exercise bout.
- Body weight
- Vital signs will be assessed prior to supplementation, 60 minutes post ingestion, and approximately 3.5 hr post-ingestion.
Study Schematic:
Informed Consent: Visit 1 Inclusion/Exclusion Criteria: Visit 1 Medical History: Visit 1 Height, weight, and BMI: Visits 1, 2, 3, 4 24-hr Dietary recall: Visit 1 CBC, CMP, Lipid Panel: Visit 1 Vitals (HR and BP): Visit 1 Bioimpedance Analysis (BIA) for percent body fat: Visit 1 Bench Press Throw for Upper Body Power (Tendo) @ 50%1RM approximately 90 minutes post-ingestion: Visits 2, 3, 4 Vertical Jump for Lower Body Power (Tendo) approximately 90 minutes post-ingestion: Visits 2, 3, 4 Lower body exercise bout consisting of squats on a Smith machine (6 x 10 @70%1RM) beginning approximately 2 hours post-ingestion: Visits 2, 3, 4 Cognitive performance battery (N-back, Flanker, Stroop) (60 min post ingestion and approximately 3 hours post-ingestion on visits 2-4 only): Visits 1, 2, 3, 4 Serum GH (before ingestion and 5, 15, 30, and 60 min post lower body exercise bout): Visits 1, 2, 3, 4 VAS (mood, motivation, alertness, and concentration) 60 min post ingestion and approximately 3 hours post-ingestion): Visits 2, 3, 4 Vitals (HR and BP) monitoring (at baseline, 60 min post ingestion, and approximately 3.5 hours post-ingestion): Visits 2, 3, 4 24 hr Diet Records/Analysis/Repeat: Visits 2, 3, 4 Protocol Compliance (diet and physical activity log check): Visits 2, 3, 4 Dispense Test Product: Visits 2, 3, 4 Adverse Events Monitoring: Visits 1, 2, 3, 4
METHODS AND INSTRUMENTATION:
- Health history will be determined using a standardized (IRB-approved) questionnaire.
- Heart rate and blood pressure will be measured using an automated sphygmomanometer.
- Body composition will be measured using a bioimpedance device (InBody 570- https://inbodyusa.com/products/inbody570/).
- Standing height will be determined using a wall-mounted stadiometer.
- Body weight and height will be measured using a Seca Medical Scale (https://www.hogentogler.com/seca/769-physician-scale.asp?gclid=EAIaIQobChMIxoqxi6ef8wIVtmpvBB34QAwzEAQYAyABEgIVIPD_BwE).
- Upper and lower body muscular power will be determined using a Tendo power analyzer (Tendo Sport- https://www.tendosport.com/products/tendo-unit/overview/)
- A Central Lab (LabCorp, Dublin, OH) will be utilized to transport and analyze all blood samples.
- Diet records will be analyzed using the online application (Nutritionix).
- Conditions
- Cognition - Other, Strength Outcomes
- Being tested
- Placebo, 315 mg Alpha-GPC, 630 mg Alpha-GPC
- Keywords
- Cognition, Mental Acuity, Performance, Nootropic, Mental, Acute supplementation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PlaceboDietary supplement
Maltodextrin
315 mg Alpha-GPCDietary supplement
350 mg of 90% pure alpha-GPC (315 mg)
630 mg Alpha-GPCDietary supplement
700 mg of 90% pure alpha-GPC (630 mg)
| Study group | Role | What they receive |
|---|---|---|
| Placebo | Placebo comparator | Placebo Receives: Dietary Supplement: Placebo |
| Low Dose Alpha-GPC | Active comparator | 315 mg dose of alpha-glycerylphosphorycholine (alpha-GPC) Receives: Dietary Supplement: 315 mg Alpha-GPC |
| High Dose Alpha-GPC | Active comparator | 630 mg dose of alpha-glycerylphosphorycholine (alpha-GPC) Receives: Dietary Supplement: 630 mg Alpha-GPC |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cognitive Performance-NBack
The N Back cognitive performance test (https://www.lumosity.com/app/v4/games/speed-match-overdrive-web )
Measured: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during visits 2, 3, and 4
Cognitive Performance
Flanker Cognitive Performance Test (https://www.psytoolkit.org/experiment-library/flanker.html)
Measured: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during visits 2, 3, and 4
Cognitive Performance
Stroop Color Matching Test
Measured: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during visits 2, 3, and 4
Secondary outcomes (9)
Lower Body Power
Vertical Jump for Lower Body Power (Tendo)
Measured: Assessed 90 minutes post-ingestion during each study visit
Upper Body Power
Bench Press Throw for Upper Body Power (Tendo) @ 50%1RM
Measured: Assessed 90 minutes post-ingestion during each study visit
Growth Hormone
Serum Growth Hormone Concentrations
Measured: Assessed before exercise and 5, 15, 30, and 60 minutes after exercise during visits 2, 3, and 4
Perceived mood assessed using visual analog scale
Perceived mood assessed using the Visual Analog Scale (VAS), a 0-100 scale where 0 indicates 'worst mood imaginable' and 100 indicates 'best mood imaginable.' Higher scores represent better perceived mood.
Measured: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during visits 2, 3, and 4
Perceived motivation assessment using visual analog scales
Perceived motivation assessed using the Visual Analog Scale (VAS), with a range of 0-100 where 0 indicates 'no motivation' and 100 indicates 'maximum motivation.' Higher scores represent better perceived motivation.
Measured: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during visits 2, 3, and 4
Perceived Alertness Assessment Using Visual Analog Scale (VAS)
Perceived alertness assessed using the Visual Analog Scale (VAS), with a range of 0-100 where 0 indicates 'no alertness' and 100 indicates 'maximum alertness.' Higher scores represent better perceived alertness.
Measured: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during visits 2, 3, and 4
Perceived Concentration Assessment Using Visual Analog Scale (VAS)
Perceived concentration assessed using the Visual Analog Scale (VAS), with a range of 0-100 where 0 indicates 'no concentration' and 100 indicates 'maximum concentration.' Higher scores represent better perceived concentration.
Measured: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during visits 2, 3, and 4
Non-exertional Heart Rate Measurement
Heart rate measured in a non-exertional state using an automated sphygmomanometer.
Measured: Assessed 60 minutes after ingestion of assigned test product and approximately 3.5 hours after ingestion during visits 2, 3, and 4
Non-exertional Blood Pressure Measurement (Systolic and Diastolic)
Blood pressure measured in a non-exertional state using an automated sphygmomanometer. Both systolic and diastolic pressures will be assessed.
Measured: Assessed 60 minutes after ingestion of assigned test product and approximately 3.5 hours after ingestion during visits 2, 3, and 4
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Nov 2024
- Study start9 Jan 2024
- Primary completion11 Jun 2024
- Study completion11 Jun 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Cognition - OtherStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- N/A. Full detail provided in Study Description
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- Lindenwood University
- Sponsor type
- University, hospital or other
- Collaborators
- NNB Nutrition
- Responsible party
- Sponsor
- Investigators
- Tim Ziegenfuss, PhD, Principal investigator, Center for Applied Health Sciences
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06690619
- Sponsor's protocol ID
- NNB-001-012024
- Status last verified
- Nov 2024
- First submitted
- 12 Nov 2024
- Last updated
- 15 Nov 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: No plan to share IPD.
Publications
Kerksick CM. Acute Alpha-Glycerylphosphorylcholine Supplementation Enhances Cognitive Performance in Healthy Men. Nutrients. 2024 Dec 9;16(23):4240. doi: 10.3390/nu16234240.
PubMed 39683633
Study at a glance
From the registry record, last updated by the sponsor on 15 Nov 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Alpha-GPC on Muscle Power, GH Levels, and Cognitive Function
- ClinicalTrials.gov ID
- NCT06690619
- Acronym / sponsor ID
- NNB-001-012024
- Conditions
- Cognition - Other, Strength Outcomes
- Keywords
- Cognition, Mental Acuity, Performance, Nootropic, Mental, Acute supplementation
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- Lindenwood UniversityUniversity, hospital or other
- Collaborators
- NNB Nutrition
- Study start
- 9 Jan 2024 (actual)
- Primary completion
- 11 Jun 2024 (actual)
- Study completion
- 11 Jun 2024 (actual)
- First posted
- 15 Nov 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Purpose: To determine the effects of low dose and high dose Alpha-GPC on cognitive performance, muscle performance, and serum growth hormone levels.
Design: Randomized, three-arm, within-subject crossover
Study Participants: 21 apparently healthy men to be recruited at a single investigational center in Northeast Ohio
4 Study Visits
Study Visit 1: Participants will be screened for participation (i.e., medical history, routine blood work, background baseline diet)
Study Visit 2: Participants will ingest one of three supplements (a low dose α-GPC, a high dose α-GPC, or a placebo). Subjects will complete visual analog scale (VAS) questionnaires (assessing mood, motivation, alertness, and concentration) and a cognitive battery (Stroop, Flanker, and N-Back tests) 60 min post ingestion and approximately 3 hours post-ingestion, undergo upper body and lower body power testing and a lower body bout of moderate-intensity exercise 90 min post-ingestion. Also, subjects will undergo blood draws for levels of growth hormone at baseline (prior to supplementation) and 5, 15, 30, and 60 min post lower body bout of exercise. Vital signs and comprehensive side effect profile/ adverse event monitoring will take place throughout the duration of the study. The study will be conducted following ICH-GCP guidelines to ensure subject safety and scientific integrity of the data.
Study Visit 3 and 4 Identical to visit 2 with exception of different supplementation being provided. Supplement administration was randomized using a Latin square approach to reduce variability and enhance statistical power
Primary Outcomes: Upper and lower body peak force production, peak power production, and peak velocity
Secondary Outcomes: Cognitive performance on the Stroop test, Flanker, and N-Back test, serum growth hormone levels, mood, motivation, alertness, and concentration (as assessed by visual analog scales).
Tertiary/Safety Outcomes: Vital signs, side effect profile/AE monitoring
Detailed description
DIET:
- All subjects will be asked to maintain their usual dietary habits throughout the study.
- At screening, all subjects will complete a 24-hour diet recall from the day prior while refraining from any nutrients that might affect choline.
- To replicate screening conditions as closely as possible, subjects will follow their previously recorded 24-hour diet record and fast for 8 hours prior to each laboratory visit.
- An online application (Nutritionix) will be used to analyze their dietary consumption.
BLOODWORK:
•Blood draws will take place during each laboratory visit, and they will be performed by a study nurse or phlebotomist. At screening a single blood draw will be performed with a total blood volume of approximately 12 mL. During visits 2-4 serial blood draws will be performed before and 5-, 15-, 30-, and 60-min post ingestion of the investigational product. During visits 2-4, an intra-venous catheter (flexible tubing to enable blood sampling) will be inserted into an upper extremity vein. Blood samples will be collected up to 5 times over 4 hours.
EXERCISE TRAINING AND PHYSICAL ACTIVITY CONTROL
•Subjects will be asked to maintain their activities of daily living and abstain from exercise for 48 hours prior to each trial.
TEST PRODUCTS
- After qualifying for the study, subjects will be randomly assigned to receive a placebo, a low dose of α-GPC, and a high dose of α-GPC using a Latin Square design.
- Low dose of α-GPC (350 mg)
- High dose of α-GPC (700 mg)
- Placebo (containing maltodextrin)
- Supplements will be provided in identical-looking capsules with label directions and Study Protocol Number.
- Subjects will consume each supplement in the presence of the medical staff.
- There will be no less than one week between each trial, though this may be longer depending on scheduling.
- As stated earlier, subjects who withdraw from the study prior to completing all three trials may be replaced.
DETAILED STUDY PROCEDURES
Visit 1 (Screening)
- Medical history, safety blood work (CBC, CMP, and Lipid Panel)
- Body composition (bioimpedance-BIA)
- Baseline diet (24hr recall).
- Body weight
- Familiarization trial for the cognitive battery (Stroop, Flanker, and N-Back test).
Visits 2-4
- Subjective feelings of mood, motivation, alertness, and concentration will be assessed 60 minutes post ingestion and approximately 3 hours post-ingestion. All assessments will be made using 100 mm anchored visual analogue scales (VAS).
- Three repetitions of the Stroop (2-min tests), Flanker, and N-Back (90s tests) tests will be assessed 60 minutes post ingestion and approximately 3 hours post-ingestion.
- Stroop - https://www.psytoolkit.org/lessons/stroop.html
- Flanker - https://www.psytoolkit.org/experiment-library/flanker.html
- N-Back - https://www.lumosity.com/app/v4/games/speed-match-overdrive-web
- Upper and lower body muscular power will be assessed with a Tendo unit. For the upper body, the bench press throw using a submaximal load (i.e., 50% of 1RM) will be performed on a Smith machine. For the lower body, a vertical jump will be performed. Both tests will be performed 90 minutes post-ingestion.
- Moderate intensity lower body exercise bout consisting of 6 sets of 10 repetitions at 70% of 1RM of squats using a metronome for cadence (15 reps per min) on a Smith machine approximately 2 hours post-ingestion.
- Growth hormone will be measured via blood draw before supplementation ingestion and 5, 15, 30, and 60 min post lower body exercise bout.
- Body weight
- Vital signs will be assessed prior to supplementation, 60 minutes post ingestion, and approximately 3.5 hr post-ingestion.
Study Schematic:
Informed Consent: Visit 1 Inclusion/Exclusion Criteria: Visit 1 Medical History: Visit 1 Height, weight, and BMI: Visits 1, 2, 3, 4 24-hr Dietary recall: Visit 1 CBC, CMP, Lipid Panel: Visit 1 Vitals (HR and BP): Visit 1 Bioimpedance Analysis (BIA) for percent body fat: Visit 1 Bench Press Throw for Upper Body Power (Tendo) @ 50%1RM approximately 90 minutes post-ingestion: Visits 2, 3, 4 Vertical Jump for Lower Body Power (Tendo) approximately 90 minutes post-ingestion: Visits 2, 3, 4 Lower body exercise bout consisting of squats on a Smith machine (6 x 10 @70%1RM) beginning approximately 2 hours post-ingestion: Visits 2, 3, 4 Cognitive performance battery (N-back, Flanker, Stroop) (60 min post ingestion and approximately 3 hours post-ingestion on visits 2-4 only): Visits 1, 2, 3, 4 Serum GH (before ingestion and 5, 15, 30, and 60 min post lower body exercise bout): Visits 1, 2, 3, 4 VAS (mood, motivation, alertness, and concentration) 60 min post ingestion and approximately 3 hours post-ingestion): Visits 2, 3, 4 Vitals (HR and BP) monitoring (at baseline, 60 min post ingestion, and approximately 3.5 hours post-ingestion): Visits 2, 3, 4 24 hr Diet Records/Analysis/Repeat: Visits 2, 3, 4 Protocol Compliance (diet and physical activity log check): Visits 2, 3, 4 Dispense Test Product: Visits 2, 3, 4 Adverse Events Monitoring: Visits 1, 2, 3, 4
METHODS AND INSTRUMENTATION:
- Health history will be determined using a standardized (IRB-approved) questionnaire.
- Heart rate and blood pressure will be measured using an automated sphygmomanometer.
- Body composition will be measured using a bioimpedance device (InBody 570- https://inbodyusa.com/products/inbody570/).
- Standing height will be determined using a wall-mounted stadiometer.
- Body weight and height will be measured using a Seca Medical Scale (https://www.hogentogler.com/seca/769-physician-scale.asp?gclid=EAIaIQobChMIxoqxi6ef8wIVtmpvBB34QAwzEAQYAyABEgIVIPD_BwE).
- Upper and lower body muscular power will be determined using a Tendo power analyzer (Tendo Sport- https://www.tendosport.com/products/tendo-unit/overview/)
- A Central Lab (LabCorp, Dublin, OH) will be utilized to transport and analyze all blood samples.
- Diet records will be analyzed using the online application (Nutritionix).
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
- Model description
- N/A. Full detail provided in Study Description
| Arm | Type | Receives |
|---|---|---|
| Placebo | Placebo comparator | Dietary Supplement: PlaceboPlacebo |
| Low Dose Alpha-GPC | Active comparator | Dietary Supplement: 315 mg Alpha-GPC315 mg dose of alpha-glycerylphosphorycholine (alpha-GPC) |
| High Dose Alpha-GPC | Active comparator | Dietary Supplement: 630 mg Alpha-GPC630 mg dose of alpha-glycerylphosphorycholine (alpha-GPC) |
Who may qualify
- Ages
- 25 to 55 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (9 listed)
- Voluntarily provide signed and dated informed consent.
- Be in good health as determined by medical history and routine blood chemistries.
- Age between 25 and 55 years (inclusive).
- Body Mass Index of 18.5-34.9 (inclusive).
- Body weight of at least 120 pounds.
Key exclusion criteria (18 listed)
- Highly trained or competitive athletes.
- History of diabetes, asthma, gout, fibromyalgia or clinical diagnosis of IBS/IBD.
- History of malignancy in the previous 5 years except for non-melanoma skin cancer (basal cell cancer or squamous cell cancer of the skin).
- History of psychiatric disorder.
- History of hepatorenal, musculoskeletal, autoimmune, or neurologic disease.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PlaceboMaltodextrin | Dietary supplement | Placebo |
| 315 mg Alpha-GPC350 mg of 90% pure alpha-GPC (315 mg) | Dietary supplement | Low Dose Alpha-GPC |
| 630 mg Alpha-GPC700 mg of 90% pure alpha-GPC (630 mg) | Dietary supplement | High Dose Alpha-GPC |
Primary outcome
Cognitive Performance-NBack
Time frame: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during visits 2, 3, and 4
The N Back cognitive performance test (https://www.lumosity.com/app/v4/games/speed-match-overdrive-web )
Cognitive Performance
Time frame: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during visits 2, 3, and 4
Flanker Cognitive Performance Test (https://www.psytoolkit.org/experiment-library/flanker.html)
Cognitive Performance
Time frame: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during visits 2, 3, and 4
Stroop Color Matching Test
9 secondary outcomes
Lower Body Power
Time frame: Assessed 90 minutes post-ingestion during each study visit
Upper Body Power
Time frame: Assessed 90 minutes post-ingestion during each study visit
Growth Hormone
Time frame: Assessed before exercise and 5, 15, 30, and 60 minutes after exercise during visits 2, 3, and 4
Perceived mood assessed using visual analog scale
Time frame: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during visits 2, 3, and 4
Perceived motivation assessment using visual analog scales
Time frame: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during visits 2, 3, and 4
Perceived Alertness Assessment Using Visual Analog Scale (VAS)
Time frame: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during visits 2, 3, and 4
Perceived Concentration Assessment Using Visual Analog Scale (VAS)
Time frame: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during visits 2, 3, and 4
Non-exertional Heart Rate Measurement
Time frame: Assessed 60 minutes after ingestion of assigned test product and approximately 3.5 hours after ingestion during visits 2, 3, and 4
Non-exertional Blood Pressure Measurement (Systolic and Diastolic)
Time frame: Assessed 60 minutes after ingestion of assigned test product and approximately 3.5 hours after ingestion during visits 2, 3, and 4
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Nov 2024.
- Derived from this study: PubMed 39683633Kerksick CM. Acute Alpha-Glycerylphosphorylcholine Supplementation Enhances Cognitive Performance in Healthy Men. Nutrients. 2024 Dec 9;16(23):4240. doi: 10.3390/nu16234240.
- Individual participant dataSharing planned: No. No plan to share IPD.
Related trials for Cognition - Other
RecruitingObservational study
InRAD Observational Study
Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI)
Recruiting
REACH Study (Recovery Environments: Assessing Cognitive & Brain Health in Community Mental Health)
Schizophrenia, Schizo Affective Disorder
Not yet recruitingObservational study
Chinese University-Alzheimer's Disease With Vascular and Other Co-pathology: Towards Actionable Neuro-Cognitive-Omic Evaluations (CU-ADVANCE)
Alzheimer s Disease, Mild Cognitive Impairment (MCI)
Not yet recruiting
NEURO-COGS: Neurometabolic Mechanisms of Cognitive Training in Schizophrenia
Schizophrenia, Schizoaffective Disorder
Active, not recruiting
Targeting Social Function in Anxiety and Eating Disorders
Eating Disorders, Anorexia Nervosa
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Tim Ziegenfuss, PhD principal investigator
Center for Applied Health Sciences
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing 315 mg Alpha-GPC and 630 mg Alpha-GPC in people with Cognition - Other and Strength Outcomes, run by Lindenwood University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cognitive Performance-NBack (time frame: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during visits 2, 3, and 4). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06690619, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Nov 2024.